[Clinical use of thrombopoietin (c-Mpl Ligand)].

作者
R Borota,J Borota,A Belić,E Gebauer,Neda Stefanović
出处
期刊:PubMed [National Institutes of Health]
卷期号:51 (11-12): 501-8 被引量:1
链接
标识
摘要

INTRODUCTION: Results in clinical use of thrombopoietin have been published later than of other hematopoietic growth factors, because until recently the research was the least understood aspect of blood cell development. Reasons for this time gap were numerous, from inconvenient methods for measurement of thrombopoietin activity, to difficulties of its chemical purification. It is claimed recently that the understanding of platelet production has been profoundly advanced by the recombinant-gene synthesis and characterization of c-Mpl ligand (Megakaryocyte Growth and Development Factor), a substance which strongly enhances the proliferation of megakaryocytic line and the production of platelets. In this paper, some historical facts and biology of thrombopoietin are briefly discussed as well as the recent of the clinical use of thrombopoietin. THE HISTORY OF RESEARCH AND PRODUCTION OF THROMBOPOIETIN: The concept that the platelet production is underlying humoral regulation was first promoted by a group of Hungarian authors and they also named that humoral regulator--thrombopoietin. Further research followed in several countries including our own, and the initial studies proved that the serum of thrombocytopenic animals induced proliferation and maturation of megakaryocytic cell line and thrombocytosis in the peripheral blood of recipient animals. Later, when in vitro techniques were developed, it was shown that this humoral regulator has also a colony stimulating activity on megakaryocytic precursors. During the following two decades, studies of megakarycytopoiesis supported the hypothesis that two types of factors are involved in platelet production: early acting--megakaryocyte colony stimulating factors (Meg-CSF), and late acting--megakaryocyte potentiators, first of all thrombopoietin (TPO). However, extensive attempts on the purification of substances that either stimulate megakaryocyte development or augment platelet production failed to yield a homogeneous protein adequate for protein sequencing and cDNA cloning, the usual route which led to the production of other hematopoietic growth factors. Furthermore, a large number of other cytokines were described that possessed activity in various assays of megakaryocyte development. In spite of great number of accumulated data, it seemed in early 1990s that the production of a distinct, clinically useful lineage specific thrombopoietin will not be soon possible to achieve. The breakthrough occurred in 1994, when four groups of investigators published simultaneously their successful results on production of c-Mpl ligand, a substance which specifically binds to the Mpl receptors on megakaryocytes and has a very potent thrombocytopoietic effect. This production is based on genetic engineering and two companies (Kirin and Amgen) are already able to produce recombinant human thrombopoietin in large amounts, for clinical use. Although this substance is not commercially available yet, it passed the preclinical and clinical trials whose results are presented here. RESULTS OF THE PRECLINICAL TRIALS OF RECOMBINANT THROMBOPOIETIN: The chemical structure of human recombinant thrombopoietin (rTPO) is well defined, it is a glycoprotein consisting of 353 amino acids and molecular weight of 30 kD. The biologic actions of this molecule are in vitro: stimulation of megakaryocyte colony forming, endoreduplication of chromosomes and megakaryocyte maturation, and in vivo: increase of the number of progenitors and of megakaryocytes in the bone marrow, and an extensive elevation of platelet count in the peripheral blood 4-7 days after its application. Also, in synergism with other pluripotent cytokines, it can stimulate the proliferation of other progenitors including CD34+ stem cells. Based on these data it is considered that c-Mpl ligand is the main physiological humoral regulator of thrombocytopoiesis, having the biological actions both of MegCSF and TPO.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
爆米花的应助被Vincent采纳,获得10
3秒前
7秒前
HAPPY完成签到,获得积分10
8秒前
桐桐的应助被Vincent采纳,获得10
9秒前
keleboys完成签到 ,获得积分10
11秒前
HMZ完成签到 ,获得积分10
13秒前
14秒前
HU完成签到 ,获得积分10
16秒前
17秒前
21秒前
小尾巴完成签到 ,获得积分10
24秒前
章鱼行者完成签到,获得积分10
24秒前
鲁文杰发布了新的文献求助10
25秒前
Maestro_S的应助被Vincent采纳,获得10
27秒前
28秒前
万能图书馆的应助被Vincent采纳,获得10
34秒前
34秒前
水静完成签到,获得积分10
35秒前
川川完成签到 ,获得积分10
39秒前
40秒前
科研通AI6.4的应助被Vincent采纳,获得10
40秒前
41秒前
标致访旋完成签到,获得积分10
42秒前
烂漫墨镜完成签到 ,获得积分10
45秒前
20230054发布了新的文献求助10
47秒前
47秒前
隐形曼青的应助被Vincent采纳,获得10
49秒前
鲁文杰完成签到,获得积分10
52秒前
52秒前
整齐百褶裙完成签到 ,获得积分10
57秒前
Changhiwi完成签到 ,获得积分10
58秒前
李健的小迷弟的应助被Vincent采纳,获得10
59秒前
59秒前
彳系禾完成签到 ,获得积分10
1分钟前
Jzhaoc580完成签到 ,获得积分10
1分钟前
冷艳凡灵完成签到,获得积分10
1分钟前
花果茶百道完成签到 ,获得积分10
1分钟前
1分钟前
一定长完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577437
关于积分的说明 21852521
捐赠科研通 7788988
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995